EUVIMEDEUVIMED entdecken
Crossref

Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis

Thi A Nguyen iD, Anh T Nguyen, Luong V Dinh, Hoa B Nguyen, Hoa D Vu iD, Tram N B Nguyen iD, Dang Vu, Nieko C Punt, Greg J Fox, Sophie L Stocker iD, Jan-Willem C Alffenaar iD

European Respiratory Journal · 2026-06 · 67 (6) · 2501875

DOI: 10.1183/13993003.01875-2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 22.01.2026. Verfasst von Thi A Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Levofloxacin, Linezolid, Tuberculosis, Multidrug-Resistant, Saliva. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Health and Medical Research Council Centre of Research Excellence in Tuberculosis, National Foundation for Science and Technology Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic drug monitoring may optimise treatment outcomes in patients with multidrug-resistant tuberculosis, yet current methods are invasive and resource intensive. This study evaluated the feasibility of using saliva point-of-care testing to screen for suboptimal exposure to levofloxacin and linezolid.

Methods

We conducted a community-based cross-sectional study in Vietnam (2021–2023). Drug concentrations were measured in paired plasma and saliva samples at 0, 2 and 5 h post-dose, using a point-of-care test (NanoPhotometer NP80) in comparison with liquid chromatography-mass spectrometry. Drug exposure (area under the drug concentration–time curve from 0 to 24 h (AUC 0–24 )) was calculated using a Bayesian population pharmacokinetic approach (Edsim++). Therapeutic targets were defined as a free AUC 0–24 to minimum inhibitory concentration ratio of 160 for levofloxacin and 125 for linezolid. Receiver operating characteristic curve analyses were conducted to determine optimal saliva thresholds for predicting subtherapeutic or supratherapeutic plasma exposure.

Results

A saliva exposure threshold of 70.3 mg·h·L −1 accurately identified 16 out of 19 patients with subtherapeutic levofloxacin plasma exposure (sensitivity 84%, specificity 78%; n=60). For linezolid (n=17), saliva testing correctly identified the only patient with subtherapeutic exposure and the only patient with supratherapeutic exposure. However, no saliva exposure thresholds could be determined.

Conclusions

Saliva-based point-of-care testing may predict the plasma drug exposure of levofloxacin and linezolid, thus enabling the detection of patients at risk of suboptimal drug exposure. This non-invasive tool warrants further investigation to establish a saliva-based threshold for linezolid and to evaluate the clinical impact and cost-effectiveness of saliva-guided drug dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinLinezolidTuberculosis, Multidrug-ResistantSalivaPoint-of-Care TestingDrug MonitoringAntitubercular AgentsHumansFemaleMaleAdultCross-Sectional StudiesMiddle AgedBayes TheoremROC CurveFeasibility StudiesArea Under CurveRapid Diagnostic Tests

Substanzen

LevofloxacinLinezolidAntitubercular Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Department of Pharmacy, Westmead Hospital, Parramatta, Australia.
  • Sydney Infectious Diseases Institute, The University of Sydney, Sydney, Australia.
  • Woolcock Institute of Medical Research, Hanoi, Vietnam.
  • The University of Sydney Vietnam Institute, Ho Chi Minh City, Vietnam.
  • National Lung Hospital, Hanoi, Vietnam.

ORCID-Profile: Thi A Nguyen, Hoa D Vu, Tram N B Nguyen, Sophie L Stocker, Jan-Willem C Alffenaar

Förderung

  • National Health and Medical Research Council Centre of Research Excellence in Tuberculosis
  • National Foundation for Science and Technology Development

Zitieren

APA

Nguyen, T. A., Nguyen, A. T., Dinh, L. V., Nguyen, H. B., Vu, H. D., Nguyen, T. N. B., Vu, D., Punt, N. C., Fox, G. J., Stocker, S. L., & Alffenaar, J. C. (2026). Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis. European Respiratory Journal, 67(6), 2501875. https://doi.org/10.1183/13993003.01875-2025

Vancouver

Nguyen TA, Nguyen AT, Dinh LV, Nguyen HB, Vu HD, Nguyen TNB, et al. Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis. European Respiratory Journal. 2026;67(6):2501875. doi:10.1183/13993003.01875-2025

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Thi A and Nguyen, Anh T and Dinh, Luong V and Nguyen, Hoa B and Vu, Hoa D and Nguyen, Tram N B and Vu, Dang and Punt, Nieko C and Fox, Greg J and Stocker, Sophie L and Alffenaar, Jan-Willem C},
  title = {Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {6},
  pages = {2501875},
  doi = {10.1183/13993003.01875-2025}
}
Kostenlos starten →